InterCure Ltd.

NASDAQ:INCR

Drug Manufacturers - Specialty & Generic

Healthcare
$3.98 -3.97%

-$0.04 today

Market cap
$51.63M
Beta
0.57
P/E (TTM)
-4.3
EPS (TTM)
-$0.64
52W Low $0.68High $1.77

Volume 0.01M

Average 0.04M

INCR Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

InterCure Ltd.NASDAQ: INCR

Revenue · Q2 FY2025 · quarter ended Jun 2025

Revenue growth accelerates

Q2 FY2025 revenue of ₪65.01M rose 3.4% year over year, ahead of the -10.8% change in trailing-twelve-month revenue. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -11.4% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether next quarter's revenue reaches the consensus estimate of ₪66.9M, a +18.3% change from the same quarter last year.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2025
₪65.01M+0.0% QoQ
Last fiscal yearDec 2025
₪270.2M+13.1% YoY
LTMJun 2025
₪243.12M-10.8% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.4%+18.3%+14.9 pp
1 year+13.1%——
3-year CAGR-11.4%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

ILS · from the income statement

Latest · FY2025
270.2M ILS
Year-over-year change
+13.1%
4-year CAGR
+5.3%

Revenue vs competitors

How INCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -10.8% is the 5th highest of 6, against a peer median of +3.3%.
  • Over three fiscal years its annual growth of -11.4% compares with a peer median of -4.6%.
INCR Competitors
Revenue for INCR and competitors
Company Period LTM YoY 3-year CAGR
INCRInterCure Ltd.LTM Jun 2025₪243.12M ILS-10.8%-11.4%
AMWLAmerican Well CorporationLTM Mar 2026$237.38M USD-9.3%-3.5%
ASRTAssertio Holdings, Inc.LTM Mar 2026$102.16M USD-14.2%-8.7%
FBIOFortress Biotech, Inc.LTM Mar 2026$66.16M USD+14.5%-5.8%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$18.36M CAD+3.3%+8.2%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$3.93M USD+160.5%—
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$0 CAD——
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$0 USD——
BMEABiomea Fusion, Inc.LTM Mar 2026$0 USD——
Peer median (excluding INCR) —+3.3%-4.6%

Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

ILS
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue219.68M388.68M355.55M238.85M270.2M
Cost of Revenue128.55M233.6M250.46M208.61M237.02M
Gross Profit91.13M155.08M105.1M30.23M33.18M
Gross Margin41.5%39.9%29.6%12.7%12.3%
Research & Development1.24M632K388K414K390K
Selling, General & Admin53.46M97.32M86.24M84.63M80.41M
Operating Expenses62.95M104.46M146.66M97.44M26.45M
Depreciation & Amortization7.39M11.7M13.17M15.37M17.15M
EBITDA31.17M70.23M(23.9M)(51.31M)(7.29M)
EBITDA Margin14.2%18.1%-6.7%-21.5%-2.7%
Operating Income28.19M50.63M(41.57M)(67.21M)6.73M
Operating Margin12.8%13.0%-11.7%-28.1%2.5%
Interest Income130K844K4.55M2.7M1.56M
Interest Expense5.05M14.69M24.22M20.65M19.66M
Other Income / Expenses(9.45M)(6.79M)(19.72M)(20.12M)(50.84M)
Income Before Tax18.74M43.84M(61.29M)(87.32M)(44.1M)
Pre-Tax Margin8.5%11.3%-17.2%-36.6%-16.3%
Income Tax Expense11.44M93K2.25M(14.53M)(7.32M)
Net Income4.69M44.82M(61.96M)(67.8M)(35.71M)
Net Margin2.1%11.5%-17.4%-28.4%-13.2%
EPS (Basic)0.120.99(1.36)(1.42)(0.63)
EPS (Diluted)0.110.99(1.36)(1.42)(0.63)
Weighted Avg Shares38.49M45.35M45.56M47.77M56.8M
Weighted Avg Shares (Diluted)40.84M45.35M45.57M47.77M56.8M

InterCure Ltd.

NASDAQ:INCR

Intrinsic Alpha fair value

Locked

Current Price

$3.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.